You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

88 Results
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Palliative
Apr 2018
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Aug 2021
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Palliative
Jun 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Curative, Palliative
Feb 2021
Regimen
Cancer Type:
Endocrine, 
Adrenal
Intent: Palliative
Funding:
ODB - General Benefit
    mitotane
Nov 2021
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Palliative
Mar 2018
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2021
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Jun 2021

Pages